Digest Network Come funziona
Network
/
Società
De
Non verificato

Delve Bio, Inc.

Di cosa scriviamo

BiotecnologiaEventiHIV, AIDS e malattie autoimmuniIndustriaSalute

8 comunicati stampa

Guarda tutti i comunicati
14/11/2025
Eventi
Biotecnologia
HIV, AIDS e malattie autoimmuni
Salute
Scienza
Presentations at Association for Molecular Pathology 2025 Annual Meeting Spotlight Clinical Impact of Delve Bio’s Metagenomic Sequencing Test for Improving CNS Diagnosis
Fonte
Delve Bio, Inc.
Emittente
Business Wire
1.00
0
20/10/2025
Scienza
HIV, AIDS e malattie autoimmuni
Biotecnologia
Medicina - Varie
Salute
Farmaceutica
Eventi
Fiere
Industria
New Data Show Early Use of Delve Bio’s Metagenomic Testing Can Reduce Need for Conventional Tests and Overall Length of Stay for Patients with Meningitis/Encephalitis
Fonte
Delve Bio, Inc.
Emittente
Business Wire
1.00
0
22/06/2025
Salute
HIV, AIDS e malattie autoimmuni
Biotecnologia
Medicina - Varie
Farmaceutica
Eventi
Industria
New Data Show Delve Bio’s Metagenomic Testing Delivers Broader, Deeper Pathogen Identification Compared to Traditional Testing
Fonte
Delve Bio, Inc.
Emittente
Business Wire
1.00
0
07/05/2025
Eventi
Industria
HIV, AIDS e malattie autoimmuni
Salute
Biotecnologia
New Data Show Delve Bio’s Metagenomic Platform Accurately Identifies Viruses and Their Subtypes With a Single Test
Fonte
Delve Bio, Inc.
Emittente
Business Wire
1.00
0
07/04/2025
Eventi
Industria
Salute
HIV, AIDS e malattie autoimmuni
Medicina - Varie
Scienza
Delve Bio to Present on Metagenomic Next Generation Sequencing (mNGS) at the American Academy of Neurology 2025 Annual Meeting
Fonte
Delve Bio, Inc.
Emittente
Business Wire
1.00
0
04/12/2024
Industria
Attrezzature medico-sanitarie
Salute
HIV, AIDS e malattie autoimmuni
Scienza
Biotecnologia
Delve Bio Announces Launch of its Groundbreaking Genomic Infectious Disease Test, Delve Detect
Fonte
Delve Bio, Inc.
Emittente
Business Wire
1.00
0
21/11/2024
HIV, AIDS e malattie autoimmuni
Salute
Medicina - Varie
Industria
Delve Bio Presents Data Showing Metagenomic Next-Generation Sequencing (mNGS) Delivers Greater Diagnostic Yield Than Conventional Methods in Central Nervous System Infections
Fonte
Delve Bio, Inc.
Emittente
Business Wire
1.00
0
12/11/2024
Industria
Biotecnologia
HIV, AIDS e malattie autoimmuni
Salute
Scienza
Delve Bio and UCSF Publish Research Demonstrating Clinical Utility of Metagenomic Next-Generation Sequencing (mNGS) for Diagnosing Serious Neurological Infections
Fonte
Delve Bio, Inc.
Emittente
Business Wire
1.00
0

Recapiti

Social Media

Seguaci
0
Compatibilità
0